In vitro activity of new fluoroquinolones and linezolid against nontuberculous mycobacteria

被引：41

作者：

Díaz, JCR ^{[1
]}

López, M ^{[1
]}

Ruiz, M ^{[1
]}

Royo, G ^{[1
]}

机构：

[1] Univ Miguel Hernandez, Hosp Gen Univ Elche, Secc Mirocbiol, Elche 03203, Alicante, Spain

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2003年 / 21卷 / 06期

关键词：

fluoroquinolones; linezolid; non-tuberculous mycobacteria;

D O I：

10.1016/S0924-8579(03)00048-7

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The objective of the study was to determine the activity of new fluoroquinolones and linezolid against 108 clinical isolates of different species of non-tuberculous mycobacteria isolated in Spain. Gatifloxacin and moxifloxacin were found to be more effective than levofloxacin. Mycobacterium kansasii was more susceptible to the fluoroquinolones tested than M. avium complex and M. fortuitum was more susceptible than M. chelonae. Linezolid was more active against M. kansasii than against M. avium complex. A better understanding of the relationship between the in vitro activity of these compounds and their usefulness in the treatment of these infections is needed. The new fluoroquinolones exhibit good activity against M. kansasii and M. fortuitum and linezolid is active against M. kansasii. (C) 2003 Elsevier Science B.V. and the International Society of Chemotherapy. All rights reserved.

引用

页码：585 / 588

页数：4

共 25 条

[1] Impact of the human immunodeficiency virus epidemic on detection of Mycobacterium isolates in a general hospital [J].

Bouza, E ;

Albadalejo, J ;

Cercenado, E ;

Serrano, MJR ;

Vicente, T ;

Ortega, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (04) :1013-1015

[2] MINIMAL INHIBITORY CONCENTRATIONS OF RIFABUTIN, CIPROFLOXACIN, AND OFLOXACIN AGAINST MYCOBACTERIUM-TUBERCULOSIS ISOLATED BEFORE TREATMENT OF PATIENTS IN TAIWAN [J].

CHEN, CH ;

SHIH, JF ;

LINDHOLMLEVY, PJ ;

HEIFETS, LB .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1989, 140 (04) :987-989

[3] CLINICAL-SIGNIFICANCE OF NONTUBERCULOUS MYCOBACTERIA ISOLATES IN A CANADIAN TERTIARY CARE CENTER [J].

CHOUDHRI, S ;

MANFREDA, J ;

WOLFE, J ;

PARKER, S ;

LONG, R .

CLINICAL INFECTIOUS DISEASES, 1995, 21 (01) :128-133

[4] EPIDEMIOLOGY AND CLINICAL-SIGNIFICANCE OF NONTUBERCULOUS MYCOBACTERIA IN PATIENTS NEGATIVE FOR HUMAN-IMMUNODEFICIENCY-VIRUS IN SWITZERLAND [J].

DEBRUNNER, M ;

SALFINGER, M ;

BRANDLI, O ;

VONGRAEVENITZ, A .

CLINICAL INFECTIOUS DISEASES, 1992, 15 (02) :330-345

[5] Clinafloxacin antibacterial activity [J].

Ednie, LM ;

Jacobs, MR ;

Appelbaum, PC .

DRUGS, 1999, 58 (Suppl 2) :217-221

[6] In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials [J].

Fernández-Roblas, R ;

Esteban, J ;

Cabria, F ;

López, JC ;

Jiménez, MS ;

Soriano, F .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) :181-182

[7] In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin [J].

Fung-Tomc, J ;

Minassian, B ;

Kolek, B ;

Washo, T ;

Huczko, E ;

Bonner, D .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (04) :437-446

[8] NONTUBERCULOUS MYCOBACTERIAL INFECTIONS [J].

GINSBURG, CM .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1992, 11 (10) :875-877

[9] Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria [J].

Guillemin, I ;

Jarlier, V ;

Cambau, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2084-2088

[10] Purification and inhibition by quinolones of DNA gyrases from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. peregrinum [J].

Guillemin, I ;

Sougakoff, W ;

Cambau, E ;

Revel-Viravau, V ;

Moreau, N ;

Jarlier, V .

MICROBIOLOGY-UK, 1999, 145 :2527-2532

← 1 2 3 →